Search

Your search keyword '"Wierenga W"' showing total 84 results
Start Over Author "Wierenga W"
84 results on '"Wierenga W"'

1. Met recht naar een doeltreffender legionellapreventie : Een toekomstgerichte evaluatie van de regelgeving over legionellapreventie in leidingwaterinstallaties op basis van een wetenschappelijke en juridische analyse

Author

Wielen, P.W.J.J. van der, Wierenga, W., Oesterholt, F., Oostdijk, A., Werff, A. van der, Wielen, P.W.J.J. van der, Wierenga, W., Oesterholt, F., Oostdijk, A., and Werff, A. van der

Abstract

Het doel van deze evaluatie is om in kaart te brengen of de huidige wetenschappelijke inzichten over legionellapreventie aanleiding geven tot het wijzigen van de regelgeving en, zo ja, op welke wijze de geldende voorschriften inhoudelijk moeten worden aangepast. De onzerzoeksvraag luidt: Welke voorschriften zouden op basis van de huidige wetenschappelijke inzichten moeten worden aangepast, en op welke wijze?

Published
2021

2. Evaluatie van de Wet dieren : eindverslag

Author

Berkhout, B., Sloover, I.S., Wierenga, W., Baardewijk, S. van, Dam, F. van, Berkhout, B., Sloover, I.S., Wierenga, W., Baardewijk, S. van, and Dam, F. van

Published
2020

19. ABPP

Author

Castañer, J., primary and Wierenga, W., additional

Published
1984
Full Text
View/download PDF

45. Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study

Author

Hortensius Johanna, Kars Marijke C, Wierenga Willem S, Kleefstra Nanne, Bilo Henk JG, and van der Bijl Jaap J

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background Self-monitoring of blood glucose (SMBG), including self-regulation, is an important tool to achieve good glycemic control. However, many patients measure their glucose concentrations less often than is recommended. This study investigates patients' perspectives of SMBG and all relevant aspects influencing SMBG in patients with type 1 and insulin-treated type 2 diabetes. Methods In depth interviews were conducted with 13 patients with type 1 diabetes from an outpatient clinic and 15 patients with type 2 diabetes from general practices. All interviews were transcribed verbatim and analyzed using the Grounded Theory approach. Results A wide variety of SMBG was encountered. Perceptions, goals of SMBG and personal and contextual factors were identified, influencing the respondents' perspective of SMBG, and leading to this variety. Respondents experienced a discrepancy between their own and the professionals' perceptions and goals. Respondents' perception of SMBG ranged along a continuum from 'friend' to 'foe'. With respect to the goals, the respondents experienced tension between achieving good glycemic control and quality of life, and deliberately made their own choices. The performance of SMBG was tailored to their perceptions and personal goals. Personal and contextual factors such as hypo- or hyper (un)awareness, knowledge, and contact with professionals acted as either facilitating factors or as barriers to SMBG, depending on the respondents' perspective. A SMBG model was developed providing a representation of the factors and their interrelations. Respondents with type 1 diabetes seemed more resigned to their situation and SMBG was more integrated into their lives. Conclusions From the patients' perspective, professionals positively present SMBG as a 'friend' in order to achieve strict glycemic control. Whereas patients can also perceive SMBG as a 'foe'. They primarily seek a personal balance between achieving glycemic control and quality of life, leading them to deliberately make other choices regarding SMBG performance than was recommended. Gaining insight and discussing all factors affecting SMBG will help professionals and patients come to mutually agreed goals and to tailor the performance of SMBG to the individual patient. This should result in a more optimal use of SMBG, an improved quality of life, and improved clinical parameters.

Published
2012
Full Text
View/download PDF

48. US immigration order strikes against biotech.

Author

Levin JM, Holtzman SH, Maraganore J, Hastings PJ, Cohen R, Dahiyat B, Adams J, Adams C, Ahrens B, Albers J, Aspinall MG, Audia JE, Babler M, Barrett P, Barry Z, Bermingham N, Bloch S, Blum RI, Bolno PB, Bonney MW, Booth B, Bradbury DM, Brauer SK, Byers B, Cagnoni PJ, Cali BM, Ciechanover I, Clark C, Clayman MD, Cleland JL, Cobb P, Cooper R, Currie MG, Diekman J, Dobmeier EL, Doerfler D, Donley EL, Dunsire D, During M, Eckstein JW, Elenko E, Exter NA, Fleming JJ, Flesher GJ, Formela JF, Forrester R, Francois C, Franklin H, Freeman MW, Furst H, Gage LP, Galakatos N, Gallagher BM, Geraghty JA, Gill S, Goeddel DV, Goldsmith MA, Gowen M, Goyal V, Graney T, Grayzel D, Greene B, Grint P, Gutierrez-Ramos JC, Haney B, Ha-Ngoc T, Harris T, Hasnain F, Hata YS, Hecht P, Henshaw L, Heyman R, Hoppenot H, Horvitz HR, Hughes TE, Hutton WS, Isaacs ST, Jenkins A, Jonker J, Kaplan J, Karsen P, Keiper J, Kim J, Kindler J, King R, King V, Kjellson N, Koenig S, Koenig G, Kolchinsky P, Laikind P, Langer RB, Lee JJ, Leff JS, Leicher BA, Leschly N, Levin A, Levin M, Levine AJ, Levy A, Liu DR, Lodish HF, Lopatin U, Love TW, Macdonald G, Maderis GJ, Mahadevia A, Mahanthappa NK, Martin JF, Martin A, Martucci WE, McArthur JG, McCann CM, McCarthy SA, McDonough CG, Mendlein J, Miller L, Miralles D, Moch KI, More B, Myers AG, Narachi MA, Nashat A, Nelson W, Newell WJ, Olle B, Osborn JE, Owens JC, Pande A, Papadopoulos S, Parker HS, Parmar KM, Patterson MR, Paul SM, Perez R, Perry M, Pfeffer CG, Powell M, Pruzanski M, Purcell DJ, Rakhit A, Ramamoorthi K, Rastetter W, Rawcliffe AA, Reid LE, Renaud RC, Rhodes JP, Rieflin WJ, Robins C, Rocklage SM, Rosenblatt M, Rosin JG, Rutter WJ, Saha S, Samuels C, Sato VL, Scangos G, Scarlett JA, Schenkein D, Schreiber SL, Schwab A, Sekhri P, Shah R, Shenk T, Siegall CB, Simon NJ, Simonian N, Stein J, Su M, Szela MT, Taglietti M, Tandon N, Termeer H, Thornberry NA, Tolar M, Ulevitch R, Vaishnaw AK, VanLent A, Varsavsky M, Vlasuk GP, Vounatsos M, Waksal SG, Warma N, Watts RJ, Werber Y, Westphal C, Wierenga W, Williams DE, Williams LR, Xanthopoulos KG, Zohar D, and Zweifach SS

Subjects
Humans, Population Dynamics, Biotechnology legislation & jurisprudence, Emigration and Immigration legislation & jurisprudence, Public Policy legislation & jurisprudence
Published
2017
Full Text
View/download PDF

49. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.

Author

Lee HT, Sliskovic DR, Picard JA, Roth BD, Wierenga W, Hicks JL, Bousley RF, Hamelehle KL, Homan R, Speyer C, Stanfield RL, and Krause BR

Subjects
Acetamides, Animals, Anticholesteremic Agents chemistry, Diet, Enzyme Inhibitors chemistry, Rabbits, Rats, Sulfonamides, Sulfonic Acids chemistry, Acetates, Anticholesteremic Agents pharmacology, Enzyme Inhibitors pharmacology, Sterol O-Acyltransferase antagonists & inhibitors, Sulfonic Acids pharmacology
Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results